In Vivo Gene Editing Partnerships
ARCUS HDR Gene Insertion and Gene Excision Validated by Big Pharma and Biotech Partners
2021
![ECURE Logo](https://precisionbiosciences.com/wp-content/uploads/2021/09/iECURE_Logo.png)
- Potential first ARCUS gene insertion program to reach clinic for OTC Deficiency affecting pediatric population
- Longest-running study of in vivo gene editing in primates demonstrates safety and stability of ARCUS-mediated editing1
KEY DEAL TERMS
- Equity stake in iECURE
- Milestone payments and royalties on sales
2022
![](https://precisionbiosciences.com/wp-content/uploads/2024/02/novartis-min.png)
- Novel approach to bring sophisticated edits beyond the liver
- — Gene insertion in hematopoietic stem cells in vivo
KEY DEAL TERMS
- $75M Upfront Payments
- $1.4B Potential Milestone Payments
- Mid-single-digit to low double-digit royalties
- Wang et al, Molecular Therapy, February 2021
Ex Vivo CAR T Partnerships Enable Funding Gene Editing Platform
Precision eligible to receive up to $47M in upfront & near-term payments with >$900M in potential milestone payments
2023
![](https://precisionbiosciences.com/wp-content/uploads/2024/02/Imugene_Logo_RGB-min-uai-516x88.png-min.png)
Exclusive global license to azer-cel for cancer indications
KEY DEAL TERMS
- $29M Upfront & Potential Near-term Payments
- $198M Potential Milestone Payments
- Option to nominate up to three research programs, each with $145M potential milestone payments and tiered royalties on net sales
- Double-Digit Royalties on Net Sales
2024
![](https://precisionbiosciences.com/wp-content/uploads/2024/02/TGTX_BIG-fbca9825-1-min.png)
Exclusive global license to azer-cel for non-cancer indications, including autoimmune diseases
KEY DEAL TERMS
- $17.5M Upfront & Potential Near-term Payments
- — Mix of cash and equity with any equity purchased at 100% premium to 30-day VWAP
- $288M Potential Milestone Payments
- High-Single-Digit to Low-Double-Digit Royalties on Net Sales
Partnering is a cornerstone of our company’s growth and success.
Through these collaborations, we deepen our capabilities with new tools, new resources, and new expertise.
![Novartis Logo](https://precisionbiosciences.com/wp-content/uploads/2022/07/Novartis-Logo-1.png)
Exclusive in vivo gene editing research and development collaboration and license agreement with Novartis to develop a single ARCUS nuclease designed as a potential single-administration treatment for hemoglobinopathies including sickle cell disease and beta thalassemia.
Learn more about this partnership ›
![ECURE Logo](https://precisionbiosciences.com/wp-content/uploads/2021/09/iECURE_Logo.png)
License and collaboration agreement with iECURE to advance Precision’s PBGENE-PCSK9 candidate into Phase 1 studies and gain access to PCSK9-directed ARCUS nuclease to develop additional gene editing therapies.
Learn more about this partnership ›
![](https://precisionbiosciences.com/wp-content/uploads/2021/09/GTP-Penn-Dual-Logo-1.png)
Research, collaboration, and license agreement with the University of Pennsylvania to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease.
Learn more about this partnership ›
![Acuitas Logo](https://precisionbiosciences.com/wp-content/uploads/2021/10/Acuitas-logo-350x80-1.png)
Option agreement to evaluate Acuitas Therapeutic Inc.’s lipid nanoparticle (LNP) technology for delivery of ARCUS with rights to license, develop, and commercialize LNP-delivered ARCUS products.
![](https://precisionbiosciences.com/wp-content/uploads/2023/08/Imugene_Logo_RGB-min.png)
Global rights to azer-cel, allogeneic CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future.